HIV Drugs Segmentation
The HIV drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, the hospital pharmacies sub-segment is anticipated to hold the largest share in the market during the forecast period on account of the growing number of HIV patients. A large number of HIV patients get admitted to hospitals is estimated to boost the market growth.
Our in-depth analysis of the global market includes the following segments:
|
Medication Class |
|
|
Distribution Channel |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of HIV drugs is estimated at USD 38.62 billion.
HIV Drugs Market size was valued at USD 36.72 billion in 2024 and is likely to cross USD 79.29 billion by 2037, expanding at more than 6.1% CAGR during the forecast period i.e., between 2025-2037.
North America industry is anticipated to account for largest revenue share by 2037, on the back of presence of an ultra-modern healthcare system.
The major players in the market are F. Hoffmann-La Roche Ltd, Cipla Inc., Teva Pharmaceuticals Industries Ltd. and Janssen Global Services, LLC.
